Evidence map›Paper›PMID 28879630›Full record

Trial reportInternational journal of hematology2017

Polymorphism in IKZF1 gene affects clinical outcome in diffuse large B-cell lymphoma.

Marta Bielska, Maciej Borowiec, Dorota Jesionek-Kupnicka, Marcin Braun, Marcin Bojo, Agata Pastorczak, Ewa Kalinka-Warzocha, Monika Prochorec-Sobieszek, Tadeusz Robak, Krzysztof Warzocha and 2 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in International journal of hematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Multiple Retinal Anomalies in Wfs1-Deficient Mice.Diagnostics (Basel, Switzerland) · 2020
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Marta BielskaDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland.
Maciej BorowiecDepartment of Clinical Genetics, Medical University of Lodz, Lodz, Poland.
Dorota Jesionek-KupnickaChair of Oncology, Department of Pathology, Medical University of Lodz, Lodz, Poland.
Marcin BraunDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland.
Marcin BojoDepartment of Chemotherapy, Wojewódzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland.
Agata PastorczakDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland.
Ewa Kalinka-WarzochaDepartment of Chemotherapy, Wojewódzki Szpital Specjalistyczny im. M. Kopernika, Lodz, Poland.
Monika Prochorec-SobieszekDepartment of Diagnostic Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Tadeusz RobakDepartment of Hematology, Medical University of Lodz, Warsaw, Poland.
Krzysztof WarzochaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Wojciech MłynarskiDepartment of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, 36/50 Sporna St., 91-738, Lodz, Poland. wojciech.mlynarski@umed.lodz.pl.
Ewa Lech-MarańdaDepartment of Hematology, Institute of Hematology and Transfusion Medicine, Warsaw, Poland.
Medical University of Lodz · PLInstytut Hematologii i Transfuzjologi · PLWojewódzki Szpital Specjalistyczny Nr 2 · PLPostgraduate School of Molecular Medicine · PL

Funding

Narodowe Centrum Nauki 2013/09/N/NZ5/00822Uniwersytet Medyczny w Lodzi 502-03/2-159-02/502-14-195
6 · The paper itself

Abstract

IKZF1 encodes a transcription factor involved in B-cell maturation and differentiation. We genotyped 218 diffuse large B-cell lymphoma (DLBCL) patients and 715 unrelated controls using a TaqMan allelic discrimination assay. No statistical difference was observed in the genotype distribution of the IKZF1 rs4132601 polymorphism between DLBCL patients and controls. However, the 2-year PFS rate of patients with the IKZF1 TT genotype was 54.3% compared to 68.6% in those with the IKZF1 G+ genotypes. Moreover, the IKZF1 rs4132601 polymorphism retained its independent prognostic impact on PFS. A more pronounced effect of the IKZF1 TT genotype on PFS was detected in patients with low/intermediate low IPI-risk group. When analysis was restricted to patients with GCB-type pattern, those with the IKZF1 TT genotype achieved a lower 5-year OS rate than the patients with the IKZF1 G+ genotypes (19.6 vs. 56%). This study provides the first evidence for the association of IKZF1 variants with DLBCL outcome.

Indexed as

GenotypePolymorphism, GeneticAdultDisease-Free SurvivalFemaleHumansIkaros Transcription FactorLymphoma, Large B-Cell, DiffuseMaleMiddle AgedNeoplasm ProteinsSurvival RateIkaros Transcription FactorIKZF1 protein, humanNeoplasm ProteinsDiffuse large B-cell lymphomaGene polymorphismIKZF1

Identifiers

PMID28879630
OpenAlexW2752922712

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.